1) recombinant human thrombopoietin
重组人血小板生成因子
1.
Phase I clinical pharmacokinetics of recombinant human thrombopoietin in healthy volunteers;
重组人血小板生成因子注射液的I期临床药代动力学
2) recombinant human thrombopoietin (rhTPO)
重组人血小板生成因子
1.
Recombinant human thrombopoietin (rhTPO) is a full-length glycosylated molecule produced in a genetically modified mammalian cell line and purified by standard technique by our Chinese boffin, National First new drug.
目的: 血小板生成素(Thrombopoietin,TPO)是近年来新发现的一种造血生长因子,重组人血小板生成因子注射液(Recombinan human thrombopoietin,rhTPO)是我国科技工作者采用重组DNA技术经提纯而制成的全长糖基化人TPO重组蛋白,属于生物制品1类新药。
3) recombinant human platelet derived growth factor-BB
重组人血小板衍生生长因子-BB
1.
Our former studies have showed that the number of osteoclasts and the expression of integrin alphavbeta3 were obviously increased in the compression sides of the orthodontic tooth movement model rats after local injection the low does of recombinant human platelet derived growth factor-BB (rhPDGF-BB), meanwhile, it accelerated the rate of orthodontic tooth movement.
前期系列实验表明:在大鼠正畸牙牙周局部注射低剂量重组人血小板衍生生长因子-BB(recombinant human platelet derived growthfactor-BB,rhPDGF-BB)后,压力侧破骨细胞计数增加,整合素α_vβ_3表达增强,从而加速了正畸牙的移动。
4) recombinant human thrombopoietin
重组人血小板生成素
1.
Pharmacological and clinical evaluation for recombinant human thrombopoietin;
重组人血小板生成素的药理作用和临床评价
2.
Pharmacokinetics after subcutaneous multi-dosing of recombinant human thrombopoietin in patients with thrombocytopenia;
血小板减少患者多次皮下注射重组人血小板生成素的药代动力学研究
3.
Clinical observation on recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in solid tumor patients
重组人血小板生成素治疗实体肿瘤患者化疗后血小板减少的临床观察
5) rhTPO
重组人血小板生成素(rhTPO)
1.
Objective:To evaluate the effect and safety of rhTPO to the thrombocytopenia patients.
目的:评价重组人血小板生成素(rhTPO)对血小板减少患者的疗效和安全性。
6) rhTPO
重组人血小板生成素
1.
Recombinant human thrombopoietin (rhTPO) in treatment of chemotherapy-induced thrombocytopenia in patients with leukemia;
重组人血小板生成素治疗白血病患者化疗诱导血小板减少73例
2.
Objective To evaluate the efficacy and safety of domestic recombinant human thrombopoietin(rhTPO) in treating thrombocytopenia caused by chemotherapy in patients with solid tumors.
目的 评价国产重组人血小板生成素 (rhTPO)治疗恶性实体瘤化疗后血小板减少症的疗效和安全性。
补充资料：血小板生成
血小板生成
指血小板的发生过程。它们由骨髓巨核细胞形成，原巨核细胞经幼巨核细胞发育生成巨核细胞，其胞体很大(直径约40～ 70μm），胞核有4～16叶，胞质内先出现许多交织成网的分隔小管，将胞质分隔成许多小区，每一小区脱落就成为一个血小板。每个巨核细胞平均能生成约 2000个血小板。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条